Vogenx, Inc.
VOGXVogenx, Inc. in brief
Vogenx, Inc. is a listed company in the Biotechnology industry, based in Raleigh, North Carolina, USA. Its market value was $296 M on 30 October 2026, which makes it the 14,848th largest listed company in the world and the 2,889th largest in the USA on this site. James Green is its chief executive. Its shares trade under the symbol VOGX (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
Vogenx, Inc. timeline
- 2026
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 12 August 2026; shares registered for exchange trading on 10 August 2026.
Events of Vogenx, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #3,051 (Aug 2026) · #3,012 (Oct 2026) · #2,893 (Oct 2026)
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-5M.
SEC filings
- Nov 6, 202610-QQuarterly report · period to Sep 2026
- Nov 6, 20268-KCurrent reportResults of operations
- Oct 9, 20268-KCurrent reportDirectors or officers changed · Regulation FD disclosure
- Sep 22, 20268-KCurrent reportDirectors or officers changed · Regulation FD disclosure
- Sep 17, 202610-QQuarterly report · period to Jun 2026
- Aug 19, 20268-KCurrent reportOther events
- Aug 13, 20268-KCurrent reportBylaws amended
- Aug 12, 2026424B4IPO prospectus
- Aug 10, 2026S-1/AIPO registration (amended)
- Jul 29, 2026S-1/AIPO registration (amended)
- Jul 15, 2026S-1IPO registration
Official filings of Vogenx, Inc. with the US Securities and Exchange Commission.
Balance sheet
- Total assets
- $1 M
- Total liabilities
- $2 M
- Total equity
- $-1 M
As of December-2025
Top 30 institutional investors in Vogenx, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Janus Henderson Group Ltd. | 1,923,076 | — | 12.95% | $44 M | Nov 16, 2026 |
| 2 | Orbimed Advisors LLC | 968,621 | New | 6.52% | $22 M | Nov 16, 2026 |
| 3 | Affinity Asset Advisors, LLC | 915,000 | New | 6.16% | $21 M | Nov 13, 2026 |
| 4 | Adage Capital Partners GP, L.L.C. | 800,000 | New | 5.39% | $18 M | Nov 16, 2026 |
| 5 | Deerfield Management Company, L.P. | 635,707 | New | 4.28% | $14 M | Nov 16, 2026 |
| 6 | Longbow Finance SA | 600,202 | New | 4.04% | $14 M | Nov 13, 2026 |
| 7 | ADAR1 Capital Management, LLC | 522,175 | New | 3.52% | $12 M | Nov 16, 2026 |
| 8 | AWM Investment Company, Inc. | 258,651 | New | 1.74% | $6 M | Nov 13, 2026 |
| 9 | Acuta Capital Partners, LLC | 213,186 | New | 1.44% | $5 M | Nov 16, 2026 |
| 10 | Ikarian Capital, LLC | 208,836 | New | 1.41% | $5 M | Nov 16, 2026 |
| 11 | Logos Global Management LP | 205,000 | New | 1.38% | $5 M | Nov 16, 2026 |
| 12 | BlackRock, Inc. | 97,205 | New | 0.65% | $2 M | Nov 13, 2026 |
| 13 | KVP Capital Advisors, LP | 86,069 | New | 0.58% | $2 M | Nov 16, 2026 |
| 14 | Geode Capital Management, LLC | 77,334 | New | 0.52% | $2 M | Nov 6, 2026 |
| 15 | Vanguard Capital Management LLC | 71,029 | New | 0.48% | $2 M | Nov 13, 2026 |
| 16 | Millennium Management LLC | 65,864 | New | 0.44% | $2 M | Nov 16, 2026 |
| 17 | Boothbay Fund Management, LLC | 60,929 | New | 0.41% | $1 M | Nov 16, 2026 |
| 18 | Vanguard Fiduciary Trust Co | 34,632 | New | 0.23% | $1 M | Nov 13, 2026 |
| 19 | Ally Bridge Group (NY) LLC | 32,701 | New | 0.22% | $1 M | Nov 16, 2026 |
| 20 | Hudson Bay Capital Management LP | 21,290 | New | 0.14% | $0 M | Nov 13, 2026 |
| 21 | Marshall Wace, LLP | 19,110 | New | 0.13% | $0 M | Nov 13, 2026 |
| 22 | State Street Corp | 14,250 | New | 0.10% | $0 M | Nov 12, 2026 |
| 23 | Northern Trust Corp | 14,032 | New | 0.09% | $0 M | Nov 16, 2026 |
| 24 | Goldman Sachs Group Inc | 12,454 | New | 0.08% | $0 M | Nov 16, 2026 |
| 25 | UBS Group AG | 9,937 | New | 0.07% | $0 M | Nov 10, 2026 |
Show all 30: investors 26 to 30
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Vanguard Portfolio Management LLC | 6,062 | New | 0.04% | $0 M | Nov 13, 2026 |
| 27 | Aster Capital Management (DIFC) Ltd | 3,125 | New | 0.02% | $0 M | Nov 12, 2026 |
| 28 | Vanguard Global Advisers, LLC | 2,425 | New | 0.02% | $0 M | Nov 13, 2026 |
| 29 | Citigroup Inc | 952 | New | 0.01% | $0 M | Nov 4, 2026 |
| 30 | Morgan Stanley | 236 | New | 0.00% | $0 M | Nov 13, 2026 |
Insider trading at Vogenx, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Steven R. DelmarChief Financial Officer, Director | Conversion | +4,273 | $11.70 | $50 K | 704,273 | Form 4 |
| filed | Peter PieracciniDirector | Conversionindirect | +42,735 | $11.70 | $500 K | 42,735 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Vogenx, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
IPO: priced at $13.00, raising $81.3M · IPO calendar
Trading halts
- 2026-08-14 13:32 UTC, code LUDP, resumed 13:37 UTC
Fails to deliver
- : 674 shares at $19.92
- : 2,375 shares at $18.92
- : 3,817 shares at $19.08
- : 6,916 shares at $20.39
- : 2,394 shares at $18.75
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Vogenx, Inc. scorecard#
Passes 0 of the 2 checks that could be worked out. Fiscal year 2025; market cap of Oct 30, 2026.
Valuation0 of 1
- –P/E below its peers' medianNo P/E on file.
- ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
- –Price to sales below its peers' medianNo Price to sales on file.
- –Free cash flow yield above 5%No free cash flow yield on file.
- –Earnings yield above the 10-year Treasury yieldNo P/E on file.
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growthnot known
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
- –Net income higher than five years earlierNet income of five years earlier is not on file.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitabilitynot known
- –Profitable in the newest yearNo net income on file.
- –Profitable in each of the last five yearsFive years of net income are not on file.
- –Operating margin above its peers' medianNo operating margin on file.
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health0 of 1
- ✗Short-term assets cover short-term liabilities0.4×Current ratio 0.42 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- –Cash from operations positive in each of the last three yearsThree years of operating cash flow are not on file.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Events at Vogenx, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Directors and officers 2 · Bylaws or fiscal year changed 1 · Results announced 1
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 6, 2026
How Vogenx, Inc. compares in Biotechnology
- Market cap$296 M · higher than 51% of 726
- 🇮🇪 Amarin Corporation$297 M
- 🇺🇸 Alector, Inc.$293 M
- 🇺🇸 SAB Biotherapeutics, Inc.$291 M
- 🇩🇪 InflaRx N.V.$301 M
- 🇺🇸 Eikon Therapeutics, Inc.$290 M
- 🇺🇸 Agenus Inc.$290 M
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Vogenx, Inc.🇺🇸 | $296 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 30, 2026
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Vogenx, Inc.? Verify and update this profile — free
Show Vogenx, Inc.'s ranking on your website Get the badge
The badge updates itself as the ranking changes.